These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 23458185)

  • 1. An experimental study to identify the potential role of pharmacogenomics in determining the occurrence of oxaliplatin-induced liver injury.
    Robinson SM; Mann J; Manas DM; Mann DA; White SA
    HPB (Oxford); 2013 Aug; 15(8):581-7. PubMed ID: 23458185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model.
    Robinson SM; Mann J; Vasilaki A; Mathers J; Burt AD; Oakley F; White SA; Mann DA
    J Hepatol; 2013 Aug; 59(2):318-26. PubMed ID: 23624001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy.
    Martinez-Balibrea E; Martínez-Cardús A; Musulén E; Ginés A; Manzano JL; Aranda E; Plasencia C; Neamati N; Abad A
    Int J Cancer; 2009 Jun; 124(12):2905-10. PubMed ID: 19296535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of the Relation between the Expression of Oxaliplatin Transporters in Colorectal Cancer and Response to FOLFOX-4 Adjuvant Chemotherapy: A Case Control Study.
    Le Roy B; Tixier L; Pereira B; Sauvanet P; Buc E; Pétorin C; Déchelotte P; Pezet D; Balayssac D
    PLoS One; 2016; 11(2):e0148739. PubMed ID: 26859833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential contribution of tumour-related factors to the development of FOLFOX-induced sinusoidal obstruction syndrome.
    Robinson SM; Mann DA; Manas DM; Oakley F; Mann J; White SA
    Br J Cancer; 2013 Oct; 109(9):2396-403. PubMed ID: 24113143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mRNA gene expression correlates with histologically diagnosed chemotherapy-induced hepatic injury.
    Pilgrim CH; Brettingham-Moore K; Pham A; Murray W; Link E; Smith M; Usatoff V; Evans PM; Banting S; Thomson BN; Michael M; Phillips WA
    HPB (Oxford); 2011 Nov; 13(11):811-6. PubMed ID: 21999595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of drug transporters in the synergistic action of FOLFOX combination chemotherapy.
    Theile D; Grebhardt S; Haefeli WE; Weiss J
    Biochem Pharmacol; 2009 Dec; 78(11):1366-73. PubMed ID: 19622348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy-induced Sinusoidal Injury (CSI) score: a novel histologic assessment of chemotherapy-related hepatic sinusoidal injury in patients with colorectal liver metastasis.
    Stevenson HL; Prats MM; Sasatomi E
    BMC Cancer; 2017 Jan; 17(1):35. PubMed ID: 28061766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases.
    Andreou A; Kopetz S; Maru DM; Chen SS; Zimmitti G; Brouquet A; Shindoh J; Curley SA; Garrett C; Overman MJ; Aloia TA; Vauthey JN
    Ann Surg; 2012 Oct; 256(4):642-50. PubMed ID: 22968062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histological liver injury and surgical outcome after FOLFOX followed by a hepatectomy for colorectal liver metastases in Japanese patients.
    Komori H; Beppu T; Baba Y; Horino K; Imsung C; Masuda T; Hayashi H; Okabe H; Ootao R; Watanabe M; Takamori H; Iyama K; Baba H
    Int J Clin Oncol; 2010 Jun; 15(3):263-70. PubMed ID: 20238233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatotoxicity following systemic therapy for colorectal liver metastases and the impact of chemotherapy-associated liver injury on outcomes after curative liver resection.
    Duwe G; Knitter S; Pesthy S; Beierle AS; Bahra M; Schmelzle M; Schmuck RB; Lohneis P; Raschzok N; Öllinger R; Sinn M; Struecker B; Sauer IM; Pratschke J; Andreou A
    Eur J Surg Oncol; 2017 Sep; 43(9):1668-1681. PubMed ID: 28599872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant oxaliplatin- or irinotecan-containing chemotherapy improves overall survival following resection of metachronous colorectal liver metastases.
    Liu JH; Hsieh YY; Chen WS; Hsu YN; Chau GY; Teng HW; King KL; Lin TC; Tzeng CH; Lin JK
    Int J Colorectal Dis; 2010 Oct; 25(10):1243-9. PubMed ID: 20574727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications.
    Lentz F; Tran A; Rey E; Pons G; Tréluyer JM
    Am J Pharmacogenomics; 2005; 5(1):21-33. PubMed ID: 15727486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Splenomegaly and Its Associations with Genetic Polymorphisms and Treatment Outcome in Colorectal Cancer Patients Treated with Adjuvant FOLFOX.
    Kim MJ; Han SW; Lee DW; Cha Y; Lee KH; Kim TY; Oh DY; Kim SH; Im SA; Bang YJ; Kim TY
    Cancer Res Treat; 2016 Jul; 48(3):990-7. PubMed ID: 26790967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver injury due to chemotherapy-induced sinusoidal obstruction syndrome is associated with sinusoidal capillarization.
    Narita M; Oussoultzoglou E; Chenard MP; Fuchshuber P; Rather M; Rosso E; Addeo P; Jaeck D; Bachellier P
    Ann Surg Oncol; 2012 Jul; 19(7):2230-7. PubMed ID: 22402811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of biological agents on the prevalence of chemotherapy associated liver injury (CALI): Multicentric study of patients operated for colorectal liver metastases.
    Hubert C; Lucidi V; Weerts J; Dili A; Demetter P; Massart B; Komuta M; Navez J; Reding R; Gigot JF; Sempoux C
    Eur J Surg Oncol; 2018 Oct; 44(10):1532-1538. PubMed ID: 30093084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential expression of ATP7A, ATP7B and CTR1 in adult rat dorsal root ganglion tissue.
    Ip V; Liu JJ; Mercer JF; McKeage MJ
    Mol Pain; 2010 Sep; 6():53. PubMed ID: 20836889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases.
    Khan AZ; Morris-Stiff G; Makuuchi M
    J Hepatobiliary Pancreat Surg; 2009; 16(2):137-44. PubMed ID: 19093069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study.
    Gibbs P; Gebski V; Van Buskirk M; Thurston K; Cade DN; Van Hazel GA;
    BMC Cancer; 2014 Dec; 14():897. PubMed ID: 25487708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer.
    Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Chun HK; Lee WY; Park YS
    Med Oncol; 2010 Dec; 27(4):1277-85. PubMed ID: 19949897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.